The Chiesi Group commissioned the Biostat® Research and Development Center an observational study in the field of neonatology. This is yet another cooperation of both entities in the field of broadly understood non-interventional research.

Biostat and Chiesi will collaborate on an observational study of the drug used in the neonatal respiratory disorder syndrome.

We will be responsible for the management of the trial, including preparation of the eCRF platform for data collection, data analysis and final report - enumerates Edyta Klemba Pharma Division Director at Biostat®.

It is worth noting that this is yet another collaboration between the two entities.

Our previous projects have been successful, others are in progress. We are grateful for the trust and we are pleased that we can start cooperation on a new study in such an important field as neonatology - emphasizes Rafał Piszczek – the Chairman of the Board of Biostat.

The Chiesi Group is one of the world's leading manufacturers of modern and innovative medical solutions, focusing on several therapeutic areas, including primarily respiratory diseases with specialization in the treatment of asthma and COPD, neonatology, transplantology and rare diseases.

The company has almost 30 representative offices around the world and is present in almost 70 countries. The company's products are manufactured in 3 production sites - in Parma, Italy, in Blois-La Chaussée, France and in Santana de Parnaiba, Brazil.

> Learn more about Biostat's clinical research services